vamorolone (Pending FDA Approval)

Mechanism of Action

First-in-class steroidal anti-inflammatory drug that differs from conventional glucocorticoids by its lack of an 11β hydroxy-carbonyl group

Removal of this contact site with the glucocorticoid receptor significantly alters structure and activity associations

Additionally, unlike glucocorticoids, vamorolone is not a substrate for 11β-hydroxysteroid dehydrogenase regulatory enzymes and is a mineralocorticoid receptor antagonist

It retains subactivities associated with efficacy (transrepression, physicochemical membrane effects, synchronization of tissue remodeling), and dissociates efficacy from other subactivities associated with detrimental side effects